Literature DB >> 8541532

Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers.

A P Grigg1, A W Roberts, H Raunow, S Houghton, J E Layton, A W Boyd, K M McGrath, D Maher.   

Abstract

To define an optimal regimen for mobilizing and collecting peripheral blood progenitor cells (PBPC) for use in allogeneic transplantation, we evaluated the kinetics of mobilization by filgrastim (recombinant met-human granulocyte colony-stimulating factor [r-metHuG-CSF]) in normal volunteers. Filgrastim was injected subcutaneously for up to 10 days at a dose of 3 (n = 10), 5 (n = 5), or 10 micrograms/kg/d (n = 15). A subset of volunteers from each dose cohort underwent a 7L leukapheresis on study day 6 (after 5 days of filgrastim). Granulocyte-macrophage colony-forming cell (GM-CFC) numbers in the blood were maximal after 5 days of filgrastim; a broader peak was evident for CD34+ cells between days 4 and 6. The 95% confidence intervals (CI) for mean number of PBPC per milliliter of blood in the three dose cohorts overlapped on each study day. However, on the peak day, CD34+ cells were significantly higher in the 10 micrograms/kg/d cohort than in a pool of the 3 and 5 micrograms/kg/d cohorts. Mobilization was not significantly influenced by volunteer age or sex. Leukapheresis products obtained at the 10 micrograms/kg/d dose level contained a median GM-CFC number of 93 x 10(4)/kg (range, 50 x 10(4)/kg to 172 x 10(4)/kg). Collections from volunteers receiving lower doses of filgrastim contained a median GM-CFC number of 36 x 10(4)/kg (range, 5 x 10(4)/kg to 204 x 10(4)/kg). The measurement of CD34+ cells per milliliter of blood on the day of leukapheresis predicted the total yield of PBPC in the leukapheresis product (r = .87, P < .0001). Assuming a minimum GM-CFC requirement of 50 x 10(4)/kg (based on our experience with autologous PBPC transplantation), all seven leukapheresis products obtained at the 10 micrograms/kg/d dose level were potentially sufficient for allogeneic transplantation purposes. We conclude that in normal donors, filgrastim 10 micrograms/kg/d for 5 days with a single leukapheresis on the following day is a highly effective regimen for PBPC mobilization and collection. Further studies are required to determine whether PBPC collected with this regimen reliably produce rapid and sustained engraftment in allogeneic recipients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541532

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Transplantation of hematopoietic stem cells from the peripheral blood.

Authors:  Jan Jansen; Susan Hanks; James M Thompson; Michael J Dugan; Luke P Akard
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

2.  Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.

Authors:  M Scholz; C Engel; M Loeffler
Journal:  J Math Biol       Date:  2004-12-20       Impact factor: 2.259

3.  Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization.

Authors:  Marnie A Ryan; Kalpana J Nattamai; Ellen Xing; David Schleimer; Deidre Daria; Amitava Sengupta; Anja Köhler; Wei Liu; Matthias Gunzer; Michael Jansen; Nancy Ratner; Timothy D Le Cras; Amanda Waterstrat; Gary Van Zant; Jose A Cancelas; Yi Zheng; Hartmut Geiger
Journal:  Nat Med       Date:  2010-09-26       Impact factor: 53.440

Review 4.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

5.  Protecting the Health and Safety of Cell and Tissue Donors.

Authors:  David F Stroncek; Lee England
Journal:  ISBT Sci Ser       Date:  2015-04-01

Review 6.  G-CSF in Healthy Allogeneic Stem Cell Donors.

Authors:  Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-22       Impact factor: 3.747

Review 7.  Autologous peripheral blood stem cells: collection and processing.

Authors:  M Hansson; A Svensson; P Engervall
Journal:  Med Oncol       Date:  1996-06       Impact factor: 3.064

8.  Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.

Authors:  Giuseppe Milone; Giovanni Tripepi; Massimo Martino; Flavia Ancora; Benedetta Bartolozzi; Andrea Spadaro; Chiara Nozzoli; Alessia La Fauci; Irene Amico; Salvatore Leotta; Massimo Poidomani; Giuseppe Irrera; Pasquale Iacopino; Riccardo Saccardi; Stefano Guidi; Alberto Bosi
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

9.  Granulocyte-colony-stimulating Factor for Acute Ischemic Stroke: A Randomized Controlled Trial (STEMTHER).

Authors:  Andrey Marisovich Alasheev; Andrey Avgustovich Belkin; Ilya Naumovich Leiderman; Roman Alekseyevich Ivanov; Tatyana Mikhailovna Isakova
Journal:  Transl Stroke Res       Date:  2011-08-04       Impact factor: 6.829

10.  Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Authors:  Markus Scholz; Manuela Ackermann; Frank Emmrich; Markus Loeffler; Manja Kamprad
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.